SGCG and neoplasm: Re-challenge with EMT-6 tumor cells in mice previously experiencing a complete response resulted in tumor rejection, but tumors were not rejected when mice were re-challenged with distinct tumor cell lines, verifying adaptive immune responses against EMT-6 cells (Fig.4).SNA administration to NHP elicited both TH1-type cytokines in serum and activated immune cells including B-cells and pDCs (Fig.5).